Association of IFNL3 rs12979860 polymorphism with HCV-related hepatocellular carcinoma susceptibility in a Chinese population

References

• Pradat P, Virlogeux V, Trépo E. Epidemiology and elimination of HCV-related liver disease. Viruses. 2018;10(10):pii: E545. doi:10.3390/v10100545
   Web of Science ®Google Scholar
• Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C virus and hepatocellular carcinoma: a narrative review. J Clin Transl Hepatol. 2018;6(1):79–84. doi:10.14218/JCTH.2017.0006729607308
   PubMed Web of Science ®Google Scholar
• Matsuura K, Tanaka Y. Host genetic variations associated with disease progression in chronic hepatitis C virus infection. Hepatol Res. 2018;48(2):127–133. doi:10.1111/hepr.1304229235266
   PubMed Web of Science ®Google Scholar
• Zhang S, Qiao K, Trieu C, et al. Genetic polymorphism of epidermal growth factor rs4444903 influences susceptibility to HCV-related liver cirrhosis and hepatocellular carcinoma in a Chinese Han population. Clin Lab. 2017;63(4):845–850. doi:10.7754/Clin.Lab.2016.16120328397482
   PubMed Web of Science ®Google Scholar
• Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164–171. doi:10.1038/ng.252123291588
   PubMed Web of Science ®Google Scholar
• Bibert S, Roger T, Calandra T, et al.; Swiss Hepatitis C Cohort Study. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med. 2013;210(6):1109–1116. doi:10.1084/jem.2013001223712427
   PubMed Web of Science ®Google Scholar
• Terczyńska-Dyla E, Bibert S, Duong FH, et al.; Swiss Hepatitis C Cohort Study Group. Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun. 2014;5:5699. doi:10.1038/ncomms597225534433
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. doi:10.1038/nature0830919684573
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801. doi:10.1038/nature0846319759533
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–1109. doi:10.1038/ng.44919749757
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–1104. doi:10.1038/ng.44719749758
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P, et al.; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338–45, 1345.e1-7. doi:10.1053/j.gastro.2009.12.056
   PubMed Web of Science ®Google Scholar
• Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology. 2010;139(6):1865–1876. doi:10.1053/j.gastro.2010.10.00420950615
   PubMed Web of Science ®Google Scholar
• Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2011;8(5):257–264. doi:10.1038/nrgastro.2011.4921468124
   PubMed Web of Science ®Google Scholar
• Hayes CN, Imamura M, Aikata H, Chayama K. Genetics of IL28B and HCV–response to infection and treatment. Nat Rev Gastroenterol Hepatol. 2012;9(7):406–417. doi:10.1038/nrgastro.2012.10122641049
   PubMed Web of Science ®Google Scholar
• Eslam M, George J. Genome-wide association studies and hepatitis C: harvesting the benefits of the genomic revolution. Semin Liver Dis. 2015;35(4):402–420. doi:10.1055/s-0035-156783026676815
   PubMed Web of Science ®Google Scholar
• Eslam M, McLeod D, Kelaeng KS, et al.; International Liver Disease Genetics Consortium (ILDGC). IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet. 2017;49(5):795–800. doi:10.1038/ng.383628394349
   PubMed Web of Science ®Google Scholar
• Chinnaswamy S. Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections. Genes Immun. 2016;17(5):265–275. doi:10.1038/gene.2016.2427278127
   PubMed Web of Science ®Google Scholar
• Heim MH, Bochud PY, George J. Host - hepatitis C viral interactions: the role of genetics. J Hepatol. 2016;65(1 Suppl):S22–S32. doi:10.1016/j.jhep.2016.07.03727641986
   PubMed Web of Science ®Google Scholar
• Suo GJ, Zhao ZX. Association of the interleukin-28B gene polymorphism with development of hepatitis virus-related hepatocellular carcinoma and liver cirrhosis: a meta-analysis. Genet Mol Res. 2013;12(3):3708–3717. doi:10.4238/2013.September.19.124085431
   PubMed Web of Science ®Google Scholar
• Attallah AM, Omran D, Marie MS, et al. IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4. Br J Biomed Sci. 2018;75(4):157–162. doi:10.1080/09674845.2018.148959929914308
   PubMed Web of Science ®Google Scholar
• Chang KC, Tseng PL, Wu YY, et al. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Clin Gastroenterol Hepatol. 2015;13(5):1017–1024. doi:10.1016/j.cgh.2014.10.03525460552
   PubMed Web of Science ®Google Scholar
• Lee MH, Yang HI, Lu SN, et al. Polymorphisms near the IFNL3 gene associated with HCV RNA spontaneous clearance and hepatocellular carcinoma risk. Sci Rep. 2015;5:17030. doi:10.1038/srep1703026602024
   PubMed Web of Science ®Google Scholar
• Ibrahim MK, Salama H, Abd El Rahman M, et al. Three gene signature for predicting the development of hepatocellular carcinoma in chronically infected hepatitis C virus patients. J Interferon Cytokine Res. 2016;36(12):698–705. doi:10.1089/jir.2016.004227726464
   PubMed Web of Science ®Google Scholar
• Chang KC, Ye YH, Wu CK, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. J Formos Med Assoc. 2018;117(11):1011–1018. doi:10.1016/j.jfma.2017.11.00829254684
   PubMed Web of Science ®Google Scholar
• Fabris C, Falleti E, Cussigh A, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011;54(4):716–722. doi:10.1016/j.jhep.2010.07.01921146242
   PubMed Web of Science ®Google Scholar
• El-Awady MK, Mostafa L, Tabll AA, et al. Association of IL28B SNP with progression of Egyptian HCV genotype 4 patients to end stage liver disease. Hepat Mon. 2012;12(4):271–277. doi:10.5812/hepatmon.83522690235
   PubMed Web of Science ®Google Scholar
• Eurich D, Boas-Knoop S, Bahra M, et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation. 2012;93(6):644–649. doi:10.1097/TP.0b013e318244f77422411462
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu SL, Chen J, Li LQ. Meta-analysis of associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinoma. Onco Targets Ther. 2016;9:3249–3257. doi:10.2147/OTT.S10490427313470
   PubMed Web of Science ®Google Scholar
• Buivydiene A, Liakina V, Kashuba E, et al. Impact of the Uridine-Cytidine kinase like-1 protein and IL28B rs12979860 and rs8099917 SNPs on the development of hepatocellular carcinoma in cirrhotic chronic hepatitis C patients – a pilot study. Medicina (Kaunas). 2018;54(5):pii: E67. doi:10.3390/medicina54050067
   Web of Science ®Google Scholar
• Agúndez JA, García-Martin E, Maestro ML, et al. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One. 2012;7(5):e37998. doi:10.1371/journal.pone.003799822666430
   PubMed Web of Science ®Google Scholar
• Bochud PY, Bibert S, Kutalik Z, et al.; Swiss Hepatitis C Cohort Study Group; ANRS HC EP 26 Genoscan Study Group. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology. 2012;55(2):384–394. doi:10.1002/hep.2467822180014
   PubMed Web of Science ®Google Scholar
• Joshita S, Umemura T, Katsuyama Y, et al. Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection. Hum Immunol. 2012;73(3):298–300. doi:10.1016/j.humimm.2011.12.02122245236
   PubMed Web of Science ®Google Scholar
• Miura M, Maekawa S, Kadokura M, et al. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol Int. 2012;6(1):386–396. doi:10.1007/s12072-011-9307-622020823
   PubMed Web of Science ®Google Scholar
• Akkiz H, Kuran S, Akgöllü E, Usküdar O, Bekar A, Bayram S. The role of interleukin 28B gene polymorphism in Turkish patients with hepatocellular carcinoma. Ann Hepatol. 2014;13(6):788–795.25332265
   PubMed Web of Science ®Google Scholar
• Zekri AR, Salama H, Medhat E, et al. IL28B rs12979860 gene polymorphism in Egyptian patients with chronic liver disease infected with HCV. Asian Pac J Cancer Prev. 2014;15(17):7213–7218. doi:10.7314/apjcp.2014.15.17.721325227816
   PubMedGoogle Scholar
• Qiao K, Trieu C, Huo Z, Du Y, Hou W. Distribution of IL28B rs12979860 and rs8099917 genotypes in patients with chronic hepatitis C virus infection in Tianjin, China. Clin Lab. 2018;64(4):543–550. doi:10.7754/Clin.Lab.2017.17103629739095
   PubMed Web of Science ®Google Scholar
• Wack A, Terczyńska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol. 2015;16(8):802–809. doi:10.1038/ni.321226194286
   PubMed Web of Science ®Google Scholar
• Lasfar A, Zloza A, de la Torre A, Cohen-Solal KA. IFN-λ: a new inducer of local immunity against cancer and infections. Front Immunol. 2016;7:598 eCollection 2016. doi:10.3389/fimmu.2016.0059828018361
   PubMed Web of Science ®Google Scholar
• Lasfar A, Zloza A, Silk AW, Lee LY, Cohen-Solal KA. Interferon lambda: toward a dual role in cancer. J Interferon Cytokine Res. 2019;39(1):22–29. doi:10.1089/jir.2018.004630020822
   PubMed Web of Science ®Google Scholar
• Abushahba W, Balan M, Castaneda I, et al. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother. 2010;59(7):1059–1071. doi:10.1007/s00262-010-0831-320217081
   PubMed Web of Science ®Google Scholar
• Yan Y, Wang L, He J, et al. Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. Biomed Pharmacother. 2017;88:395–402. doi:10.1016/j.biopha.2017.01.07728122304
   PubMed Web of Science ®Google Scholar